PKI 14-22 amide, myristoylated, is a selective, cAMP-dependent, competitive PKA inhibitor with a Ki of approximately 36 nM. Its myristoylation modification enhances its permeability to cell membranes and blood-brain barriers. This compound can inhibit the phosphorylation of cAMP-dependent downstream targets like CREB and is suitable for research in opioid tolerance mechanisms and antiviral drugs.
- Selective, cAMP-dependent, competitive PKA inhibitor
- Myristoylation enhances cell membrane and blood-brain barrier permeability
- Inhibits phosphorylation of cAMP-dependent downstream targets (e.g., CREB)
- Prevents morphine analgesic tolerance in mice
- Inhibits Zika virus protein translation and RNA synthesis